Levocarnitine
Carnitor, Levocarnitine (levocarnitine) is a small molecule pharmaceutical. Levocarnitine was first approved as Carnitor on 1985-12-27. It is used to treat deficiency diseases in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Carnitor, Carnitor sf, Levocarnitine, Levocarnitine sf (discontinued: Carnitor, Levocarnitine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levocarnitine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CARNITOR | Leadiant Biosciences | N-018948 RX | 1985-12-27 | 1 products, RLD, RS |
| CARNITOR | Leadiant Biosciences | N-020182 RX | 1992-12-16 | 1 products, RLD, RS |
| CARNITOR | Leadiant Biosciences | N-019257 RX | 1986-04-10 | 1 products, RLD, RS |
| CARNITOR SF | Leadiant Biosciences | N-019257 RX | 2007-03-28 | 1 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| carnitor | New Drug Application | 2024-10-30 |
| carnitor sf | New Drug Application | 2024-11-04 |
| levocarnitine | ANDA | 2025-07-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| deficiency diseases | EFO_1001067 | D003677 | E63 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1955 | Injection, levocarnitine, per 1 gm |
Clinical
Clinical Trials
293 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | 1 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | 1 | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscular atrophy | D009133 | — | — | 1 | 2 | — | — | — | 2 |
| Spinal muscular atrophy | D009134 | EFO_0003823 | G12.1 | 1 | 2 | — | — | — | 2 |
| Atrophy | D001284 | — | — | 1 | 2 | — | — | — | 2 |
| Spinal muscular atrophies of childhood | D014897 | Orphanet_83419 | G12.1 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 1 | 1 |
| Hypoglycemia | D007003 | — | E16.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Levocarnitine |
| INN | levocarnitine |
| Description | Carnitine is an amino-acid betaine that is butanoate substituted with a hydroxy group at position C-3 and a trimethylammonium group at C-4. It has a role as a human metabolite and a mouse metabolite. It is functionally related to a butyrate. It is a conjugate base of a carnitinium. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[N+](C)(C)C[C@H](O)CC(=O)[O-] |
Identifiers
| PDB | — |
| CAS-ID | 541-15-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1149 |
| ChEBI ID | 16347 |
| PubChem CID | 288 |
| DrugBank | DB00583 |
| UNII ID | 0G389FZZ9M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Levocarnitine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 64,057 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
630 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use